Cited by 1,164Acute Myeloid Leukemia ResearchSingle-cell and spatial transcriptomicsCancer Genomics and Diagnostics

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity

Open access
van Galen, Peter, Hovestadt, Volker, Wadsworth II, Marc H., Hughes, Travis K., Griffin, Gabriel K., Battaglia, Sofia, Verga, Julia A., Stephansky, Jason +11 more·2019·Cell

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease that resides within a complex microenvironment, complicating efforts to understand how different cell types contribute to disease progression. We combined single-cell RNA sequencing and genotyping to profile 38,410 cells from 40 bone marrow aspirates, including 16 AML patients and five healthy donors. We then applied a machine learning classifier to distinguish a spectrum of malignant cell types whose abundances varied between patients and between subclones in the same tumor. Cell type compositions correlated with prototypic genetic lesions, including an association of FLT3-ITD with abundant progenitor-like cells. Primitive AML cells exhibited dysregulated transcriptional programs with co-expression of stemness and myeloid priming genes and had prognostic significance. Differentiated monocyte-like AML cells expressed diverse immunomodulatory genes and suppressed T cell activity in vitro. In conclusion, we provide single-cell technologies and an atlas of AML cell states, regulators, and markers with implications for precision medicine and immune therapies. VIDEO ABSTRACT.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2019.01.031

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TP53-sAML differed from de novo AML with an enrichment into HSC and early erythroid populations, whereas de novo AML was enriched in myeloid progenitors.

    “TP53-sAML differed from de novo AML with an enrichment into HSC and early erythroid populations, whereas de novo AML was enriched in myeloid progenitors (Fig. 2c,d)25.”

    From Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution (2023) · cites this paper as [25]

    The Results section on AML cellular hierarchies links clusters enriched for TP53 mutations to differing cell compositions, but does not compare TP53-associated secondary AML with de novo AML. Searches for secondary AML, early erythroid populations, and de novo AML with myeloid progenitors found no passage establishing the claimed contrast. The indexed passages provide no page numbers. (LLM, conf=0.73)

    Experimental — accuracy not yet measured
  • Other studies mapped cells to known reference cell types or states, using only marker genes.

    “Alternatively cells were mapped to known reference cell (sub)types or states4,5,11,12, making effective use only of cell-state or cell-type specific marker genes.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
van Galen, P., Hovestadt, V., Wadsworth II, M. H., Hughes, T. K., Griffin, G. K., Battaglia, S., Verga, J. A., Stephansky, J., Pastika, T. J., Lombardi Story, J., Pinkus, G. S., Pozdnyakova, O., Galinsky, I., Stone, R. M., Graubert, T. A., Shalek, A. K., Aster, J. C., Lane, A. A., & Bernstein, B. E.
Affiliations
  • Broad Institute (US)
  • Brigham and Women's Hospital (US)
  • Dana-Farber Cancer Institute (US)
  • Harvard University (US)
Corresponding author
Bernstein, Bradley E.
Venue
Cell
Publisher
Elsevier BV
Published
2019-03
Volume
176
Issue
6
Pages
1265-1281.e24
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2916458303
Cited by
1,164
References
38
Citations by year
2026: 151 · 2025: 189 · 2024: 168 · 2023: 175 · 2022: 165 · 2021: 156 · 2020: 127 · 2019: 31 · 2018: 1
FWCI
87.71
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
  • PMC
Funders
  • NCI
  • Leukemia & Lymphoma Society
  • HFSP
  • EMBO
  • Searle Scholars Program
  • Beckman Young Investigator Program
  • Pew-Stewart Scholars Program
  • Sloan Fellowship
  • Bill and Melinda Gates Foundation
  • NIH
  • Doris Duke Charitable Foundation
  • NHGRI
  • Ludwig Center
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
acute myeloid leukemia, tumor heterogeneity, FLT3-ITD, progenitor-like cells, stemness genes, immunomodulatory genes, T cell suppression, tumor microenvironment, subclonal heterogeneity, prognostic gene signature, bone marrow, single-cell atlas
MeSH terms
Machine Learning, Exome Sequencing, Adult, Base Sequence, Bone Marrow, Bone Marrow Cells, Female, Genotype, Humans, Male, Middle Aged, Mutation, Prognosis, RNA, Signal Transduction, Leukemia, Myeloid, Acute, Disease Progression, Cell Line, Tumor, Single-Cell Analysis, Tumor Microenvironment, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review